Jul 5, 2019

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Dr Daniel P Petrylak, Prof Thomas Powles and Dr Jonathan E Rosenberg.

• Introduction (00:00)
• Program overview: Dr Love
• Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Advanced Urothelial Bladder Carcinoma (UBC) (1:13)
• Case (Dr Petrylak): A woman in her mid-60s with metastatic UBC who experienced rapid disease progression on first-line gemcitabine/cisplatin (1:49)
• Case (Dr Rosenberg): A man in his late 70s with metastatic UBC who was ineligible for cisplatin-based chemotherapy and achieved a complete response to first-line pembrolizumab  (11:02)
• Newly Approved and Investigational Novel Agents and Strategies Beyond Immune Checkpoint Inhibition (16:44)
• Case (Dr Petrylak): A woman in her mid-60s with metastatic UBC who enrolled on a clinical trial of enfortumab vedotin and achieved a complete remission (24:42)
• Case (Prof Powles): A man in his mid-60s with metastatic UBC whose disease progressed rapidly on gemcitabine/cisplatin and pembrolizumab who began treatment with enfortumab vedotin (28:09)
• Future Applications of Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Systemic Approaches (41:26)
• Case (Dr Rosenberg): A woman in her early 60s with widespread metastatic UBC who experienced disease progression on single-agent nivolumab and was switched to nivolumab/ipilimumab (45:05)
• Case (Prof Powles): A man in his mid-60s with transitional cell carcinoma who received neoadjuvant atezolizumab on a clinical trial (54:33)

Select publications